

DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2017 [updated 17 May 2017; cited 23 September 2020]. Available from: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141(9):e139-e596.
3. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar 2018. [Internet] Jakarta: Kementerian Kesehatan Republik Indonesia; 2018. [cited 23 September 2020]. Available from: <https://www.kemkes.go.id/resources/download/info-terkini/hasil-risikesdas-2018.pdf>.
4. Dharma S, Andriantoro H, Purnawan I, Dakota I, Basalamah F, Hartono B, et al. Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. *British Medical Journal*. 2016;6(8):e012193.
5. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. *New England Journal of Medicine*. 2019;381(15):1411-21.
6. Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. *Journal of Geriatric Cardiology*. 2015;12(3):305-12.
7. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. *Blood*. 2005;105(1):199-206.
8. Qiu Y, Zhang C, Zhang G, Tao J. Endothelial progenitor cells in cardiovascular diseases. *Aging Medicine*. 2018;1(2):204-8.
9. Suades R, Padro T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. *Thrombosis and Haemostasis*. 2012;108(6):1208-19.
10. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. *Arteriosclerosis Thrombosis and Vascular Biology*. 2011;31(1):27-33.
11. Fernandez M, Calligaris SD. Circulating microparticles in cardiovascular disease: going on stage! *Biomarkers*. 2019;24(5):423-8.
12. Zhou B, Li J, Chen S, Zhou E, Zheng L, Zu L, et al. Time course of various cell origin circulating microparticles in ST-segment elevation myocardial infarction patients undergoing percutaneous transluminal coronary intervention. *Experimental and Therapeutic Medicine*. 2016;11(4):1481-6.
13. Suades R, Padro T, Crespo J, Ramaiola I, Martin-Yuste V, Sabate M, et al. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. *International Journal of Cardiology*. 2016;202:378-87.
14. Abdel Hamid M, Bakhoun SW, Sharaf Y, Sabry D, El-Gengehe AT, Abdel-Latif A. Circulating Endothelial Cells and Endothelial Function Predict Major

Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction. *Journal of Interventional Cardiology*. 2016;29(1):89-98.

15. Hartopo AB, Puspitawati I, Gharini PP, Setianto BY. Platelet microparticle number is associated with the extent of myocardial damage in acute myocardial infarction. *Archives of Medical Science*. 2016;12(3):529-37.

16. Hartopo AB, Mayasari DS, Puspitawati I, Mumpuni H. Circulating Platelet-Derived Microparticles Associated with Postdischarge Major Adverse Cardiac Events in ST-Elevation Acute Myocardial Infarction. *Cardiol Res Pract*. 2020;2020:6721584.

17. Sionis A, Suades R, Sans-Rosello J, Sanchez-Martinez M, Crespo J, Padro T, et al. Circulating microparticles are associated with clinical severity of persistent ST-segment elevation myocardial infarction complicated with cardiogenic shock. *International Journal of Cardiology*. 2018;258:249-56.

18. Ong SB, Hernandez-Resendiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. *Pharmacology and Therapeutics*. 2018;186:73-87.

19. Frangiannis NG. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. *Journal of Cardiovascular Pharmacology*. 2014;63(3):185-95.

20. Paudel KR, Panth N, Kim DW. Circulating Endothelial Microparticles: A Key Hallmark of Atherosclerosis Progression. *Scientifica*. 2016;2016:8514056.

21. Franca CN, de Oliveira Izar MC, do Amaral JB, Tegani DM, Fonseca FAH, Franca CN. Microparticles as potential biomarkers of cardiovascular disease. *Journal of Brazilian Society of Cardiology*. 2014;104(2):169-74.

22. Koganti S, Eleftheriou D, Brogan PA, Kotecha T, Hong Y, Rakhit RD. Microparticles and their role in coronary artery disease. *International journal of cardiology*. 2017;230:339-45.

23. Schiro A, Wilkinson FL, Weston R, Smyth JV, Serracino-Inglott F, Alexander MY. Endothelial microparticles as conveyors of information in atherosclerotic disease. *Atherosclerosis*. 2014;234(2):295-302.

24. Chironi GN, Simon A, Boulanger CM, Tedgui A, Dignat-George F, Freyssinet JM. Endothelial microparticles in diseases. *Cell and Tissue Research*. 2009;335(1):143-51.

25. Schillaci G, Pirro M. Endothelial microparticles and arterial stiffness: casual coincidence or causative culprit? *American Journal of Hypertension*. 2007;20(9):965-6.

26. Voukalis C, Shantsila E, Lip GYH. Microparticles and cardiovascular diseases. *Annals of Medicine*. 2019;51(3-4):193-223.

27. Simoncini S, Njock MS, Robert S, Camoin-Jau L, Sampol J, Harle JR, et al. TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. *Circulation Research*. 2009;104(8):943-51.

28. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, et al. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. *Thrombosis and Haemostasis*. 2010;104(3):456-63.

29. Steppich BA, Moog P, Matissek C, Wisniowski N, Kuhle J, Joghetaei N, et al. Cytokine profiles and T cell function in acute coronary syndromes. *Atherosclerosis*. 2007;190(2):443-51.
30. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. *Circulation*. 2002;106(18):2372-8.
31. Markiewicz M, Richard E, Marks N, Ludwicka-Bradley A. Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. *Journal of Aging Research*. 2013;2013:734509.
32. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk. *World J Cardiol*. 2017;9(5):407-15.
33. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *Journal of the American College Cardiology*. 2015;66(4):403-69.
34. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Jr., Drozda JP, Jr., et al. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). *Circulation*. 2013;127(2):65-105.
35. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. *Eur Heart J*. 2017;38(41):3056-65.
36. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Circulation*. 2018;137(24):2635-50.
37. Zaman S, Kovoor P. Sudden cardiac death early after myocardial infarction: pathogenesis, risk stratification, and primary prevention. *Circulation*. 2014;129(23):2426-35.
38. Lu Y, Li L, Yan H, Su Q, Huang J, Fu C. Endothelial microparticles exert differential effects on functions of Th1 in patients with acute coronary syndrome. *International Journal of Cardiology*. 2013;168(6):5396-404.
39. Montoro-Garcia S, Shantsila E, Tapp LD, Lopez-Cuenca A, Romero AI, Hernandez-Romero D, et al. Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. *Atherosclerosis*. 2013;227(2):313-22.
40. Abbas M, Jesel L, Auger C, Amoura L, Messas N, Manin G, et al. Endothelial Microparticles From Acute Coronary Syndrome Patients Induce Premature Coronary Artery Endothelial Cell Aging and Thrombogenicity: Role of

the Ang II/AT1 Receptor/NADPH Oxidase-Mediated Activation of MAPKs and PI3-Kinase Pathways. *Circulation*. 2017;135(3):280-96.

41. Sopiudin Dahlan. *Besar Sampel Dalam Penelitian Kedokteran dan Kesehatan*. Edisi 5 ed. Jakarta: Epidemiologi Indonesia; 2016. p. 14-19.

42. Sastroasmoro S. *Dasar-dasar metodologi penelitian klinis*. Edisi 5 ed. Jakarta: Sagung Seto; 2016. p. 247-248.

43. American Diabetes A. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. *Diabetes care*. 2019;42:13.

44. Bryer E, Stein E, Goldberg S. Multivessel Coronary Artery Disease: The Limitations of a "One-Size-Fits-All" Approach. *Mayo Clinic Proceedings*. 2020;4(6):638-41.

45. Ahmed. F, Rahman. A, Rahman. MA, Chowdhury. TA, Chowdhury. SH, Uddin. SN, et al. Predictors of Short Term Outcomes of Primary Percutaneous Coronary Intervention. *Bangladesh Heart Journal*. 2018;33(2):112-20.

46. Ipek G, Kurmus O, Koseoglu C, Onuk T, Gungor B, Kirbas O, et al. Predictors of in-hospital mortality in octogenarian patients who underwent primary percutaneous coronary intervention after ST segment elevated myocardial infarction. *Geriatric Gerontology International*. 2017;17(4):584-90.

47. Alkhouli M, Alqahtani F, Jneid H, Al Hajji M, Boubas W, Lerman A. Age-Stratified Sex-Related Differences in the Incidence, Management, and Outcomes of Acute Myocardial Infarction. *Mayo Clinic Proceedings*. 2021;96(2):332-41.

48. Guo Y, Yin F, Fan C, Wang Z. Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2018;97(30):e11644.

49. Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. *J Clin Med*. 2021;10(11).

50. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. *Arterioscler Thromb Vasc Biol*. 2013;33(7):1460-7.

51. Burgess S, Juergens CP, Yang W, Shugman IM, Idris H, Nguyen T, et al. Cardiac mortality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction. *Int J Cardiol*. 2021;323:13-8.

52. Steele L, Palmer J, Lloyd A, Fotheringham J, Iqbal J, Grech ED. The impact of smoking on mortality after acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a retrospective cohort outcome study at 3 years. *J Thromb Thrombolysis*. 2019;47(4):520-6.

53. Akhtar Z, Aleem MA, Ghosh PK, Islam A, Chowdhury F, MacIntyre CR, et al. In-hospital and 30-day major adverse cardiac events in patients referred for ST-segment elevation myocardial infarction in Dhaka, Bangladesh. *BMC Cardiovascular Disorder*. 2021;21(1):85.

54. Kazazi EH, Sheikvatan M, Mahmoodian M, Fathollahi MS, Sadeghian H. Comparing angiography features of inferior versus anterior myocardial infarction regarding severity and extension in a cohort of Iranian patients. *J Res Med Sci*. 2011;16(4):484-9.

55. Gupta T, Weinreich M, Kolte D, Khera S, Villablanca PA, Bortnick AE, et al. Comparison of Incidence and Outcomes of Cardiogenic Shock Complicating

Posterior (Inferior) Versus Anterior ST-Elevation Myocardial Infarction. *Am J Cardiol.* 2020;125(7):1013-9.

56. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart Journal.* 2017;70(12):1082.

57. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. *Circulation.* 2021;144(0):e18.

58. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. *Euro Heart Journal.* 2016;37(13):1024-33.

59. Berezin AE, Berezin AA. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. *Disease Markers.* 2020;2020:1215802.

60. Liehn EA, Postea O, Curaj A, Marx N. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. *Journal of the American College Cardiology.* 2011;58(23):2357-62.

